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There is increasing use of antipsychotic drugs in pediatric and psychiatry practice for a wide range of behavioral and aﬀective
disorders. These drugs have prominent side eﬀects of interest to pediatric endocrinologists, including weight gain and associated
metabolic risk factors and hyperprolactinemia. The drugs block dopamine action, thus disinhibiting prolactin secretion.
Hyperprolactinemia is especially prominent with ﬁrst-generation antipsychotics such as haloperidol and the second-generation
drugs, most commonly risperidone, with some patients developing gynecomastia or galactorrhea or, as a result of prolactin
inhibition of gonadotropin releasing hormone from the hypothalamus, amenorrhea. With concern about the long-term eﬀects
of antipsychotics on bone mass and pituitary tumor formation, it is prudent to monitor serum prolactin levels in antipsychotic
drug-treated pediatric patients and consider treatment with an agent less likely to induce hyperprolactinemia.
1.Introduction
The practice of psychiatry and the shift to noninstitutional
care of severe psychiatric disorders are the result of antipsy-
chotic medications, beginning with chlorpromazine in the
early 1950s. Approximately 10 other drugs, known as ﬁrst-
generationortypicalantipsychotics,followedoverthesubse-
quent 30 years. These drugs were eﬀective in treating positive
symptoms of psychosis such as hallucination and delusion
but did not alleviate the negative symptoms of withdrawal,
apathy, cognitive impairment, or loss of aﬀect. Furthermore,
they were associated with frequent extrapyramidal symp-
toms, including acute dystonia, akinesia, akathisia, tardive
dyskinesia, and parkinsonism. A series of newer drugs began
emerging in 1989, referred to as second generation or atypi-
calantipsychotics,thoughttobemoreeﬀectivethantheolder
agents in alleviating the negative, cognitive, and aﬀective
symptoms, with fewer extrapyramidal adverse eﬀects [1].
The antipsychotic drugs diﬀer in their side eﬀect proﬁles,
as they aﬀect diﬀerent neuroreceptors (histamine, α-adren-
ergic, muscarinic, dopamine, or serotonin). The principal
concern for endocrinologists with the newer drugs has been
the metabolic eﬀects of weight gain, glucose intolerance,
hyperlipidemia, and hypertension [2]. This is particularly
important with the increasing use of these agents in pedi-
atrics to treat bipolar disorder, schizophrenia, autism, oppo-
sitional and other behavior disturbances, Tourette disorder,
and pervasive developmental disorder. In 2003-2004, 1% of
all pediatric visits resulted in the prescription of atypical
antipsychotic medication [3]. The importance and implica-
tions of the metabolic side eﬀects of atypical antipsychotics
for pediatric patients have been recently reviewed [1, 4].
This paper will examine the side eﬀect of hyperpro-
lactinemia in children and adolescents treated with antipsy-
chotic drugs.
2.Physiology
Prolactin, a 198-amino acid polypeptide, is secreted by the
anterior pituitary lactotroph cells in a pulsatile manner
with 13-14 peaks per day, the peak amplitude ∼60%
above nadir [5]. There is also a marked circadian variation
with maximum secretion ∼4 hours from sleep onset and2 International Journal of Pediatric Endocrinology
minimum ∼6 hours after waking [6]. Thus, there can be as
much as a fourfold variation in level depending on the time
of day or night sampling is done; there are also transient
mild increases related to meals, stress, and sexual activity [7].
Prolactinlevelsarehigherduringmenstrualmidcycleandthe
2nd half of the cycle. During pregnancy, levels rise 10–20-
fold, reaching 200μg / La tt e r ma n d3 0 0μg/L during nursing
[8]. Normal upper limit range is 15–25μg/L [7].
Prolactin stimulates breast enlargement during preg-
nancy and milk production during lactation, while reducing
libido and fertility, which may have evolutionary/survival
signiﬁcance.
Secretion of prolactin is inhibited predominantly by
dopamine produced in the tuberoinfundibular neurons of
the hypothalamus, released from nerve endings in the
median eminence and carried through the portal hypophy-
seal circulation to the pituitary, there binding to dopamine
D2 receptors on lactotrophs, inhibiting prolactin gene tran-
scription [9]. Antipsychotic drugs are thought to disinhibit
prolactin secretion by D2 receptor blockade. Serotonin
stimulates prolactin secretion via serotonin 5-HT1A and 5-
HT2 receptors. Estrogens, binding to speciﬁc intracellular
receptors in lactotrophs, enhance prolactin gene transcrip-
tion and synthesis [6]. They also inhibit dopamine synthesis
in the tuberoinfundibular neurons and reduce D2 receptor
levels on lactotrophs in animal models [10, 11].
3. Effects of Hyperprolactinemia
Gonadotropin releasinghormone(GnRH),releasedinapul-
satile manner from the hypothalamus, stimulates release of
luteinizing hormone (LH) and follicle stimulating hormone
(FSH) from the anterior pituitary. Prolactin inhibits the
release of GnRH in the hypothalamus. The positive feedback
of estradiol on LH secretion in women is also blocked. Con-
sequently, estrogen levels in women and testosterone levels
in men are suppressed, with marked individual variability in
the prolactin level causing gonadal hypofunction.
In children and adolescents, hyperprolactinemia result-
ing from prolactinomas, which are rare, can result in
galactorrhea, amenorrhea, gynecomastia, and maturational
delay with growth failure [12]. Of concern is the potential
eﬀectof the induced hypogonadotropism state on the critical
peak bone formation of adolescence and the maintenance of
bone density through adulthood.
4. Effects of Psychotropic Drugs on
ProlactinSecretion
Psychiatric disorders may be associated with modest ele-
vations in serum prolactin concentrations as a stress phe-
nomenon [13]. Further prolactin elevation can be measured
withinminutestohoursafterthestartoftreatmentwithﬁrst-
generationantipsychoticdrugs,withlevelsupto10-foldafter
several weeks at therapeutic dosages. Levels typically fall to
normal within 2 to 4 days of stopping the drugs but may take
up to 3 weeks to return to normal [14].
In adult psychiatric patients clozapine and quetiapine
did not raise plasma prolactin levels at any dosage. Olan-
zapine only did so at higher dosages, but risperidone and
amisulpride caused marked, sustained increase in serum
prolactin levels in a substantial number of patients [14].
Aripiprazole, a relatively new atypical antipsychotic, also
does not appear to increase prolactin levels [15]. Ziprasidone
caused only transient elevations in psychiatric patients and
healthy volunteers [16].
A review published in 2004 of 14 reports of the eﬀects
of both ﬁrst- and second-generation antipsychotic agents in
children and adolescents included 276 patients of whom 49
had prolactin elevations [17]. A report of 35 patients aged
9–19 years found no prolactin elevation with clozapine, but
in 9 of 10 with haloperidol and 7 of 10 with olanzapine
[18]. In another study of 11 outpatients aged 4–17 years
treated with risperidone, 9 developed hyperprolactinemia
of whom one had amenorrhea, and one had gynecomastia
[19]. A further study reported that prolactin levels were
increased in all 34 patients aged 5–14 years treated with
risperidone [20]. Hyperprolactinemia was also noted in
pediatric patients using ziprasidone and olanzapine. As with
adults, ziprasidone- associated prolactin elevation was mild
and transient, but associated with mild gynecomastia [21]
and in one case with galactorrhea that resolved after drug
discontinuation [22]. Two studies of the eﬀects of quetiapine
led to slightly diﬀering results: one showed no increase in
prolactin levels in 10 12–15-year-old children while the other
study of 15 13–17-year-olds found a slight increase of no
clinical signiﬁcance, from a mean of 11.3 to 14.4ng/mL [17].
Clozapine was not associated with increased prolactin levels,
and the single patient who developed galactorrhea with
risperidone had resolution of the problem when switched to
clozapine [23].
A retrospective study analyzed prolactin levels and
hyperprolactinemia attributable side eﬀects from 5 clinical
trials involving 592 children and adolescents of subaverage
intelligence with conduct or other disruptive behavior
disorders aged 5 to 15 years treated with risperidone. There
was a weak eﬀect of risperidone on prolactin concentrations
during short-term treatment and lesser eﬀect with long-term
treatment, with side eﬀects of gynecomastia, amenorrhea,
or galactorrhea in only 2.2% [24]. These relatively benign
ﬁndings have been attributed to low drug dosage for
behavioral rather than psychiatric disorders and decreasing
compliance over time [25].
Quite diﬀerent ﬁndings emerged from a small double-
blind placebo-controlled study of the eﬀect of relatively low
dose risperidone on prolactinemia in 10 children and adoles-
cents with mental retardation and pervasive developmental
disorders. Prolactin levels approximately tripled, and this
increasewassustainedforamean33weeksoftreatment[26].
Three adolescents were reported with risperidone-
induced hyperprolactinemia resulting in gynecomastia in
one boy that cleared and did not recur with olanzapine,
gynecomastia with galactorrhea in another boy with com-
parable prolactinemia that resolved when he was switched
to clozapine, and amenorrhea and galactorrhea in the third
patient that resolved when she was changed to quetiapine.International Journal of Pediatric Endocrinology 3
Their prolactin levels were 2100, 1670, and 1990mIU/L (58,
46, and 55μg/L) when they were hyperprolactinemic and
reduced to 63, 90, and 191mIU/L (2, 2.5, and 5.3 μg/L)
afterresolution[27].Among10psychoticadolescentstreated
with risperidone, Holzer and Eap had 3 males developing
gynecomastia and 2 females developing galactorrhea, along
with 3 others having hyperprolactinemia without symptoms
[25].
Sixteen adolescents aged 13–17 years with subaver-
age intelligence and disruptive behavior disorders treated
with olanzapine for 8 weeks had signiﬁcant elevations in
serum prolactin levels, from baseline 9.7 ± 6.1t o2 4 .8 ±
19.8(SD)μg/L without any symptoms or signs of hyperpro-
lactinemia [28].
A study from Italy compared short- and long-term
eﬀects on prolactin of risperidone and olanzapine in 42
children and adolescents treated for a year [29]. They found
that after adjusting for dose and the greater potency of
risperidone, the increase in prolactin levels during risperi-
done treatment was 10.7 times higher than that during
olanzapine treatment. Only one subject had a symptom
of hyperprolactinemia, transient mild galactorrhea with
risperidone which resolved without a change in therapy.
Similarly, a randomized comparison of quetiapine and
risperidonein2215–18-year-oldadolescentswithnew-onset
psychosis found prolactin elevation in 91% of those treated
with risperidone versus 9% of those treated with quetiapine
[30].
Dutch investigators have recently conducted an extensive
literature review of studies of antipsychotic medication
eﬀects on prolactin level and associated side eﬀects in
children and adolescents [31]. They found 29 publications
with study durations longer than 3 weeks. Twenty of these
were concerning risperidone, 7 olanzapine, 5 quetiapine,
4 haloperidol, 3 pimozide, 2 clozapine, and 1 ziprasidone.
They found that all antipsychotics with the exception of
clozapine, ziprasidone, and quetiapine increased the mean
prolactin level from 8 to 25–28ng/mL. The incidence of
hyperprolactinemia was 90% with haloperidol, 80% with
pimozide, 62% with risperidone, 31% with olanzapine,
and 12% with quetiapine. Risperidone, olanzapine, and
pimozide were seen to induce a persistent elevation in
prolactin levels. Associated gynecomastia, galactorrhea, or
irregular menses were reported in 4.8% of the children
and adolescents. Data from this review and subsequent
reports are summarized in Table 1. Interpretation of the
numerousstudiesisconfoundedbyvariationinstudydesign,
diagnoses, dosages, and age distribution, varying use of
concomitant medication, short duration of some studies,
compliance uncertainty, lack of prolactin baseline values
(one fourth of the studies analyzed by Roke et al. [31]), and
other missing data as noted in the table. Furthermore, single
measurements of prolactin are subject to diurnal variation
and stress inﬂuence. There may also be publication bias, as
all data on prolactin values from manufacturers’ ﬁles have
not been published [31]. The eﬀects of hyperprolactinemia
may be underestimated because they depend on self-report,
and may be mistaken for common adolescent problems of
gynecomastia and irregular menstrual cycles.
The degree of hyperprolactinemia induced by short-
term risperidone treatment in children and youth is dose
dependent[17,33].Thisdosedependencyislinkedtoplasma
concentrations of both risperidone and its active metabolite
9-hydroxyrisperidone [33]. CYP2D6 is primarily responsible
for the conversion of risperidone to 9-hydroxyrisperidone.
In an examination of the possible role of activity of this
enzyme in risperidone-induced prolactin release in children,
Troost et al. [34] found a positive correlation of the fourfold
elevationinserumprolactinlevelat8and24weekswithdose
per kilogram body weight (r = 0.65, P<. 001), number
of functional CYP2D6 genes, serum 9-hydroxyrisperidone
concentration (r = 0.66, P<. 001) and negative correlation
with the risperidone/9-hydroxyrisperidone ratio (r =− 0.57,
P = .004) but not with risperidone concentration (r =
−0.24, P = .26). Thus, more rapid CYP2D6 metabolism
maybeariskfactorforhyperprolactinemiawithrisperidone.
Polymorphic variation in the dopamine D2 receptor may
be another pharmacogenetic factor determining risk for
risperidone-induced hyperprolactinemia in children and
adolescents.Twovariantswereidentiﬁedthatwereassociated
withhigherprolactinconcentrationinastudyof107patients
treated for up to 3 years [32].
Because second-generation antipsychotics are being
increasingly prescribed for children and adolescents with
conditions that are not psychoses and that are also treated
with stimulants, the potential mitigating eﬀect of the stim-
ulants on the side eﬀects of the antipsychotics has been
examined [35]. Stimulant drugs have opposite eﬀects on
the dopamine receptor than do the antipsychotics. Subjects
were 153 4–19-year-olds treated with antipsychotics, 71
of whom were coprescribed stimulants. The antipsychotic
drugs included risperidone (33%), aripiprazole (30%), que-
tiapine (18%), olanzapine (12%), and ziprasidone (6%).
In addition to no eﬀect of cotreatment with stimulants on
the side eﬀect of hyperprolactinemia, there was no eﬀect
on body composition, metabolic parameters, sedation, or
overall eﬃcacy of the antipsychotic agent.
5. PotentialLong-Term Effects of
Psychotropic Drugs
5.1. Bone Mineral Density (BMD). Antipsychotic-induced
hyperprolactinemia in adults with schizophrenia has been
associated with reduced BMD and increased fracture risk
[36, 37]. The initial report of the eﬀect of psychotropic
drugs on BMD in children was a cross-sectional study
that involved 83 boys aged 7 to 17 years treated with
risperidone for an average of 3 years and selective serotonin
reuptake inhibitors (SSRIs) [38]. With adjustment for the
stage of sexual maturation, height, and body mass index,
a negative association was found between serum prolactin
level and trabecular volumetric BMD at the distal radius.
Furthermore, treatment with SSRIs was associated with
lower trabecular BMD at the radius and BMD Z-score at the
lumbar spine. Lumbar spine BMD Z-score did not correlate
with prolactinemia. In females with prolactin secreting
tumors, hyperprolactinemia eﬀects on BMD are mediated4 International Journal of Pediatric Endocrinology
Table 1: Eﬀects of risperidone, olanzapine, haloperidol, quetiapine, clozapine, ziprasidone, and pimozide on prolactin (PRL) level and PRL
related side eﬀects [gynecomastia (GCM), galactorrhea (GLR), and irregular menses (IM) in children and adolescents. Weighted averages
(adjusted for numbers of subjects per study) are given for the analysis of Roke et al. [31] with the number of studies analyzed shown in
parentheses. Subsequent individual studies are separately indicated, with standard deviations in parentheses. Dashes indicate absent data.
Drug Number Age
(years)
Dose
(mg/day)
Duration
(weeks)
PRL
baseline
ng/mL
PRL
endpoint
ng/mL
% with
PRL >nl
upper
limit
%
GCM
%
GLR %I M
Roke et al. [31]
(20)
risperidone 1390 9.7 1.6 34.8 8.2 21.6 61.7 3.0 0.5 6.2
Migliardi et al.
[29]
risperidone 6 (female) 12.8 (2.3) 1.9 (1.1) 52 8.4 (2.1) 23.4 (7.6) — — ∗ 0
22 (male) 10.1 (2.8) 1.7 (1.2) 52 6.5 (1.9) 14.9 (8.6) — 0 — —
Swadi et al. [30] risperidone 11 <19 — 6 — — 91 — — —
Calarge et al.
[32]
risperidone 107 7–17 — mean-36 — — 50 8 11 33
Roke et al. [31]
(7)
olanzapine 170 14.4 2.7 28 11.1 24.2 31 6.2 2.8 2.4
Migliardi et al.
[29]
olanzapine 6 (female) 14.3 (2.1) 6.7 (3) 52 8.8 (3.8) 18 (5.2) — — 0 0
7( m a l e ) 14 (1.9) 7.5 (2.5) 52 7.8 (2.4) 11.3 (4.9) — 0 — —
Swadi et al. [30] olanzapine 11 <19 — 6 — — 9 — — —
Roke et al. [31]
(5) quetiapine 72 13.9 378.5 49.6 8.4 9.3 0 0 0 0
(4) haloperidol 56 12.7 7.2 6.5 7.7 29.1 90 6.7 0 15.4
(3) pimozide 46 10.3 3.7 21.2 9.3 24.7 80 — — —
(2) clozapine 30 14.5 270 6 9.6 11.6 0 0 0 0
(1) ziprasidone 6 14.5 (1.8) 98 (40) 8.6 (6.6) 8.6 (6.6) 12 (8) 0 0 0 0
∗One individual transiently without dosage change.
by hypogonadism [39]. However, in this study, serum
testosterone concentrations, adjusted for maturational stage,
were not aﬀected by hyperprolactinemia, suggesting a direct
eﬀect of the hyperprolactinemia on bone turnover [38].
Prolactin receptors have been found in osteoblasts, and
animal studies indicate that hyperprolactinemia activates
the phosphoinositide 3-kinase pathways via the prolactin
receptors to suppress alkaline phosphatase activity [40].
The ﬁnding that SSRI treatment was associated with
r e d u c e dB M Dc o u l dr e ﬂ e c ta ne ﬀect on prolactinemia.
However, no independent eﬀect of SSRIs on prolactin
concentration was found in an earlier study by these
authors[32],andthenegativeassociationbetweenSSRIsand
BMD was found after adjustment for numerous covariates
including prolactinemia. Serotonin has a role in osteoclast
diﬀerentiation and activity [41]. The study of Calarge et al.
[38] is limited by the dependence on a single measurement
of serum prolactin which can vary by time of day and
stress level, and absence of measures of bone turnover. The
authors recognize that it is premature to make any deﬁnitive
conclusions about the eﬀect of psychotropic medications on
bone mineralization [38].
5.2. Pituitary Tumors. Noting higher-than-expected post-
marketing reports of pituitary tumors associated with
risperidone, Szarfman et al. [42] analyzed patterns of these
tumors in the United States Food and Drug Adminis-
tration Adverse Event (AE) Reporting System database.
They sought disproportionate reporting patterns of pituitary
tumor reports for antipsychotics with diﬀerent aﬃnities for
blocking D2 receptors (aripiprazole, clozapine, olanzapine,
quetiapine, risperidone, ziprasidone, and haloperidol). The
rankorderofthestrengthoftheassociationbetweenthedrug
and the development of pituitary tumors corresponded to
theaﬃnityofthese7drugsfortheD2receptor.Inchildren7–
18 years of age, there was 1 AE of pituitary tumor associated
with olanzapine and 3 with risperidone. The authors note
the importance of these ﬁndings for children because the
symptoms of a pituitary expanding mass may not be as
readily evaluated in those with mental illness or serious
behavioral problems and that delayed detection can result in
hemorrhage or optic nerve compression.
6. Conclusion
Second-generation antipsychotics are being increasingly pre-
scribed for children and adolescents with a wide range of
behavioral disturbances in addition to psychoses, result-
ing in metabolic and hormonal changes of importance
to the consulting pediatric endocrinologist. In addition
to weight gain and associated comorbidities of insulin
resistance, hyperprolactinemia is a common side eﬀectInternational Journal of Pediatric Endocrinology 5
resulting from the inhibition of dopamine action. First-
generation antipsychotics, particularly haloperidol, and the
second-generation antipsychotic drugs, most prominently
risperidone, appear to be associated with the greatest risk
for hyperprolactinemia; some treated individuals developing
hyperprolactinemia will have galactorrhea, amenorrhea, or
gynecomastia. Hyperprolactinemia may have a deleterious
eﬀect on peak bone mass attainment and increase long-
term osteopenia risk, even in the absence of overt symptoms
or signs of hyperprolactinemia. This adverse eﬀect may be
enhanced by the commonly associated treatment with SSRIs.
The eﬀect of psychotropic drugs on bone mass accrual needs
further study. The suggestion of a greater risk for pituitary
tumors related to drug aﬃnity for D2 receptors also requires
continued study. Thus, in addition to surveillance for
signs and symptoms of hyperprolactinemia in children and
adolescents taking antipsychotic medications, monitoring
serum prolactin concentrations is warranted. In the presence
of hyperprolactinemia, cessation of antipsychotic therapy or
changing to a formulation less likely to raise prolactin levels
should be considered.
Disclosure
The author is a consultant to a law ﬁrm pursuing litiga-
tion with manufacturers of second-generation antipsychotic
drugs.
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